| 13.12.2024 10:04 | AZN, HCM | IN BRIEF: Hutchmed to get Takeda milestone payment | Alliance |
| 03.12.2024 12:19 | HCM | Hutchmed China injection approval could be a "paradigm shift" | Alliance |
| 03.12.2024 10:00 | HCM | HUTCHMED and Innovent Announce ELUNATE Approval | Reach |
| 29.11.2024 08:30 | HCM | Total Voting Rights | RNS |
| 28.11.2024 10:32 | HCM | Continued Inclusion of ORPATHYS in China NRDL | Reach |
| 22.11.2024 10:00 | HCM | Hutchmed to get payment from Takeda as Fruzaqla launched in Japan | Alliance |
| 22.11.2024 07:00 | HCM | FRUZAQLA® Launched in Japan by Takeda | Reach |
| 20.11.2024 09:30 | HCM | Appointment of Independent Non-executive Director | RNS |
| 06.11.2024 07:00 | HCM | Clinical Data to be Presented at ASH and ESMO Asia | Reach |
| 31.10.2024 12:02 | HCM | Hutchmed China receives first milestone payment for Takeda drug sales | Alliance |
| 31.10.2024 08:30 | HCM | First Commercial Milestone Payment | Reach |
| 31.10.2024 08:30 | HCM | Total Voting Rights | RNS |
| 21.10.2024 09:30 | HCM | Vesting of awards under the LTIP | RNS |
| 16.10.2024 09:52 | AZN, HCM | TOP NEWS: AstraZeneca's Tagrisso plus Orpathys shows promising results | Alliance |
| 16.10.2024 07:00 | HCM | SAVANNAH: clinically meaningful response rate | RNS |
| 10.10.2024 10:20 | HCM, CAML, WNWD | AIM WINNERS & LOSERS: Windward rises; Hutchmed recovers | Alliance |
| 24.09.2024 08:49 | HCM | Takeda Pharmaceutical says Fruzaqla cancer drug gets Japan backing | Alliance |
| 24.09.2024 08:00 | HCM | Japan Approval for FRUZAQLA | RNS |
| 09.09.2024 07:00 | HCM | Clinical Data to be Presented at ESMO and WCLC | Reach |
| 30.08.2024 12:24 | HCM | Hutchmed "disappointed" as it withdraws fruquintinib application | Alliance |
| 22.08.2024 09:30 | HCM | Standard form for notification of major holdings | RNS |
| 21.08.2024 09:30 | HCM | HUTCHMED to Host Expert Call to discuss ITP | Reach |
| 06.08.2024 10:00 | HCM | LTIP and Share Option Scheme | RNS |
| 31.07.2024 14:41 | HCM | Hutchmed confident of full year guidance for oncology and immunology | Alliance |
| 31.07.2024 12:00 | HCM | 2024 Interim Results and Business Updates | RNS |
| 24.07.2024 14:45 | SHC, RIO, RCDO | UK earnings, trading statements calendar - next 7 days | Alliance |
| 05.07.2024 19:08 | HCM | IN BRIEF: Hutchmed's tazemetostat given priority review in China | Alliance |
| 04.07.2024 07:00 | HCM | NDA Acceptance in China for Tazemetostat | Reach |
| 28.06.2024 12:35 | HCM | Overseas Regulatory Announcement: Form F-3 Filing | Reach |
| 28.06.2024 09:30 | HCM | Blocklisting Six Monthly Return | RNS |
| 28.06.2024 09:30 | HCM | Total Voting Rights | RNS |
| 26.06.2024 09:30 | HCM | HUTCHMED to Announce 2024 HY Financial Results | RNS |
| 24.06.2024 10:30 | HCM | Save the Date: HUTCHMED to Present R&D Updates | Reach |
| 24.06.2024 10:00 | HCM | IN BRIEF: Hutchmed China notes Takeda obtains EU approval for Fruzaqla | Alliance |
| 24.06.2024 07:00 | HCM | European Commission Approval for FRUZAQLA | RNS |
| 17.06.2024 10:32 | HCM | Hutchmed celebrates "promising" results for sovleplenib in China | Alliance |
| 17.06.2024 07:00 | HCM | Lancet Publish Phase III ESLIM-01 Results | Reach |
| 07.06.2024 18:13 | HCM | IN BRIEF: Hutchmed (China) begins trial of menin inhibitor HMPL-506 | Alliance |
| 07.06.2024 07:00 | HCM | HUTCHMED Initiates Phase I Trial of HMPL-506 | Reach |
| 03.06.2024 07:00 | HCM | Nature Medicine Publish Phase III FRUTIGA Results | Reach |
| 31.05.2024 09:30 | HCM | Total Voting Rights | RNS |
| 24.05.2024 07:00 | HCM | HUTCHMED Presentations at 2024 ASCO Annual Meeting | Reach |
| 17.05.2024 17:58 | HCM | IN BRIEF: Hutchmed China Simon To leaves role, succeeded by Dan Eldar | Alliance |
| 17.05.2024 15:00 | HCM | Retirement of Chairman and new Chairman appointed | RNS |
| 17.05.2024 07:00 | HCM | HUTCHMED Data to be Presented at EHA2024 Congress | Reach |
| 14.05.2024 14:33 | HCM | Hutchmed announces trials of HMPL-306 and Surufatinib cancer therapies | Alliance |
| 14.05.2024 07:00 | HCM | HUTCHMED Initiates Registrational Phase III Trial | Reach |
| 14.05.2024 07:00 | HCM | HUTCHMED Initiates Phase II/III Trial with Hengrui | Reach |
| 10.05.2024 13:00 | HCM | Result of AGM | RNS |
| 08.05.2024 09:30 | HCM | Directorate Change | RNS |
| 03.05.2024 13:37 | WPM, RMV, SENX | UK shareholder meetings calendar - next 7 days | Alliance |
| 26.04.2024 16:09 | HCM | Hutchmed notes CHMP's positive opinion for fruiquintinib approval | Alliance |
| 26.04.2024 13:30 | HCM | Positive CHMP Opinion for Fruquintinib | RNS |
| 22.04.2024 09:30 | HCM | Vesting of Awards Under the LTIP | RNS |
| 08.04.2024 09:30 | HCM | 2023 Annual Report and Notice of AGM | RNS |
| 05.04.2024 09:30 | HCM | Data to be Presented at AACR Congress 2024 | Reach |
| 02.04.2024 10:32 | HCM | Hutchmed endometrial cancer treatment application accepted for review | Alliance |
| 02.04.2024 07:00 | HCM | HUTCHMED and Innovent Announce NDA Acceptance | Reach |
| 28.03.2024 11:08 | HCM | Hutchmed lung cancer treatment accepted for review in China | Alliance |
| 28.03.2024 07:00 | HCM | Savolitinib sNDA Accepted in China | Reach |
| 22.03.2024 10:09 | HCM | Hutchmed begins registration stage for sovleplenib phase 2/3 trial | Alliance |
| 22.03.2024 07:00 | HCM | Initiation of Registration Stage of P2/3 Trial | Reach |
| 14.03.2024 09:00 | HCM | LTIP and Share Option Scheme | RNS |
| 05.03.2024 08:30 | HCM | Vesting of awards under the LTIP | RNS |
| 28.02.2024 17:31 | TRIG, AIQ, CRV | EARNINGS: Hutchmed revenue surges, Craven House's loss widens | Alliance |
| 28.02.2024 12:45 | HCM | Publication of Form 20-F | Reach |
| 28.02.2024 11:30 | HCM | 2023 Full Year Results and Business Updates | RNS |
| 21.02.2024 15:14 | STJ, RHIM, TRIG | UK earnings, trading statements calendar - next 7 days | Alliance |
| 07.02.2024 09:50 | HCM | Hutchmed hails fruquintinib trial results for gastric cancer treatment | Alliance |
| 07.02.2024 07:00 | HCM | Presentation of Phase III Data on Fruquintinib | Reach |
| 02.02.2024 09:52 | HCM | Hutchmed says Inmagene exercises option to licence drug candidates | Alliance |
| 30.01.2024 09:20 | HCM | Hutchmed celebrates cancer drug approval in hometown of Hong Kong | Alliance |
| 30.01.2024 07:12 | HCM | HUTCHMED Receives Marketing Approval in Hong Kong | Reach |
| 11.01.2024 10:17 | HCM | TOP NEWS: Hutchmed Sovleplenib accepted for review by China drug bureau | Alliance |
| 11.01.2024 07:00 | HCM | Sovleplenib NDA Granted Priority Review in China | Reach |
